Case-control study of changes in bone mineral density in drug-naive patients in the first-episode of schizophrenia during the first year of treatment with risperidone

Shanghai Archives of Psychiatry

Volumn 23, Issue 5, 2011, Pages 278-283

  Li, Xiaoyi ^a   Chen, Hong ^a   Chen, Xingli ^a   Xu, Fangzhong ^a   Xing, Baoping ^a  

^a Tongde Hospital   (China)

Author keywords

Bone mineral density; Risperidone; Schizophrenia

Indexed keywords

EID: 84876324020     PISSN: 10020829     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1002-0829.2011.05.004     Document Type: Article

References (13)

1. Howard L, Kirkwood G, Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry, 2007, 190: 129-134.
2. Becker D, Liver O, Mester R. Rapoport M, Weizman A, Weiss M, Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry, 2003, 64(7): 761-766.
3. Halbreich U. Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation. CNS Drugs, 2007, 21(8): 641-657.
4. Ma W Y, Sun H X, Zhang B, Yu Z J, Zhang S H, Peng J F, et al. Control study of bone mineral density in patients with schizophrenia. Journal of Qiqihar Medical College, 2006, 27(1): 15. (in Chinese)
5. Bilici M, Cakirbay H, Guler M, Tosun M, Ulgen M, Tan U. Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Int J Neurosci, 2002, 112(7): 817-828.
6. Yuan W, Dang J. Antipsychotics and osteoporosis (Analysis of 10 Cases). Journal of Clinical Psychiatry, 2006, 16 (5): 268. (in Chinese)
7. Graham S M, Howgate D, Anderson W, Howes C, Heliotis M, Mantalaris A, et al. Risk of osteoporosis and fracture incidence in patients on antipsychotic medication. Expert Opin Drug Saf, 2011, 10(4): 575-602.
8. Chinese Society of Psychiatry. Chinese Classification of Mental Disorders, Third Edition (CCMD-3). Jinan: Shandong Science & Technology Press. 2001. (in Chinese)
9. World Health Organization: Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis. Geneva, WHO, 1998: 5-6.
10. Howes O. Bone mineral density and prolactin associations in patients with chronic schizophrenia. Schizophr Res, 2004, 66 (1): 77-78.
11. Stubbs B. Antipsychotic-induced hyperprolactinaemia in patients with schizophrenia: considerations in relation to bone mineral density. J Psychiatr Ment Health Nurs, 2009, 16(9): 838-842.
12. Hu J M, Li Y, Li T, Wang H M, Liu X H, Huo K J. The effects of antipsychotics on serum prolactin in the first-episode schizophrenia patients. West China Journal of Pharmaceutical Sciences, 2003, 18(6): 467-469. (in Chinese)
13. McEvoy J P, Lieberman J A, Perkins D O, Hamer R M, Gu H, Lazarus A, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-Week comparison. Am J Psychiatry, 2007, 164(7): 1050-1060.